2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.274

Change

-0.03 (-0.41)%

Market Cap

USD 0.52B

Volume

0.19M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.89% 54% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.89% 54% F 58% F
Trailing 12 Months  
Capital Gain 19.76% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.76% 65% D 67% D+
Trailing 5 Years  
Capital Gain 42.53% 68% D+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.53% 68% D+ 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.14% 49% F 49% F
Dividend Return 5.14% 48% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.20% 46% F 56% F
Risk Adjusted Return 38.89% 41% F 45% F
Market Capitalization 0.52B 66% D+ 58% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.